Recently, the Beijing Municipal Drug Administration and the Beijing Municipal Health Commission issued a "Notice on Outstanding Units and Individuals in the Monitoring of Adverse Reactions to Drugs, Medical Devices, and Cosmetics in 2023". Beijing Beilu Pharmaceutical Co., Ltd. was honored as the "Beijing Advanced Unit for Daily Monitoring of Adverse Drug Reactions", and Zhou Chenchen from the Pharmacovigilance Department was awarded the title of "Beijing Outstanding Individual in Adverse Drug Reaction Monitoring Work". The company has received the title of "Advanced Unit for Daily Monitoring of Adverse Drug Reactions" for seven consecutive years.
Beilu Pharmaceutical takes public health as its main purpose and responsibility, committed to ensuring the right to know about drug safety information for patients and healthcare workers, and urging high-quality drug production to fully protect people's health. The company is dedicated to continuously improving its work in pharmacovigilance with a sound system, standardized processes, and professional research. Through continuous efforts, the company has formed an effective work system. Firstly, the company has established and continuously improved systems such as pharmacovigilance management, institutionalizing, standardizing, and systematizing pharmacovigilance work. Secondly, the company regularly holds training for all employees related to pharmacovigilance, strengthening the understanding of the importance of pharmacovigilance work among all employees, popularizing the responsibilities of pharmaceutical practitioners, and the reporting and handling methods of adverse drug reactions, establishing a multi-departmental, multi-channel work process for collecting and reporting drug safety information, including medical marketing, sales systems, production, and quality.
The company's Pharmacovigilance Department conducts multi-angle safety analysis on collected adverse reaction data. At the same time, the company regularly organizes in-depth analysis and judgment by experts to reduce the occurrence of adverse drug reactions and avoid unnecessary medication risks; it promptly revises instructions to ensure the right to know about drug safety information for patients and healthcare workers. As an outstanding representative, the company's Pharmacovigilance Department participated in the "Beijing-Tianjin-Hebei Pharmacovigilance Symposium" on behalf of Beijing pharmaceutical companies in 2023 and was invited to give a special lecture on understanding of pharmacovigilance, early warning systems, and quality management practices, sharing experiences in building pharmacovigilance systems.
Ensuring patient medication safety is our mission, and the significance and importance of pharmacovigilance work are self-evident. Beilu Pharmaceutical's Pharmacovigilance Department will continue to develop to high standards, practicing the company's mission of taking public health as its responsibility and fully protecting people's health.
EN
jp 
fr 
de 
es 
ru 
pt 
ar 
Iohexol Intermediate 5-Amino-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxamide
Iohexol/Ioversol Intermediate 5-Amino-N, N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxamide
Ioversol Intermediate (order based) N, N'-Bis(2,3-dihydroxypropyl)-5-(glycoloylamino)-2,4,6-triiodoisophthalamide
Iopamidol Intermediate (order based) 5-Amino-2,4,6-triiodoisophthalic acid
Iopamidol Intermediate (order based) 5-Amino-2,4,6- triiodisophthaloyl acid dichloride
Diethylenetriaminepentaacetic acid (DTPA)
Call us on: 
Email Us: 
No.3 Shuiyuan West Road, Miyun District, Beijing, China 